Joe Mixon

An apparently rare medical condition he learned about in the spring caused Mixon to miss the 2025 season, and has Texans decision-makers questioning whether he'll actually be able to return next season. Even team leadership lacks clarity on recovery timeline.

At 29.5 years old with 1,816 career carries and multiple foot/ankle injuries over two years, Mixon fits the profile of a running back past the typical value decline threshold. Even if healthy, his market value would be minimal after missing an entire season.

Mixon was released by Houston on March 6, 2026 with a failed physical designation tied to a mysterious foot condition that sidelined him the entire 2025 season. GM Nick Caserio described it as 'kind of a freak thing' and never disclosed the exact nature — the opacity itself is a red flag for dynasty buyers.

Mixon missed all of 2025 (placed on Reserve/NFI in August 2025, never activated), meaning he enters 2026 as a 30-year-old free agent with zero NFL snaps in over 18 months. At his age and position, returning from that gap at full effectiveness is historically uncommon.

With no team as of April 2026, Mixon is likely targeting a one-year prove-it deal ($4–6M) wherever his medicals clear. He has zero leverage and zero guaranteed role — landing spot quality is entirely unknowable, and most plausible destinations (Seahawks, Steelers, Chiefs) would slot him behind a starter.

Mixon was officially released by Houston on March 6, 2026 and remains unsigned through the end of April — the 'NFL TEAM: HOU' in the structured data is stale. A cold free-agent market nearly two months after his release signals serious team skepticism about his foot.

If Houston's offensive line proves solid and the coaching staff commits to a ground-game approach, Mixon could have a functional final year. However, this would be a short-term rental rather than dynasty asset.

Dynasty community has Mixon at RB61 with a value near — effectively distressed-asset pricing. If he passes a physical and clears waivers healthy, the risk-adjusted upside for a speculative flier at near-zero cost is real for rosters with roster depth.

At a the market value of (RB96 in dynasty), Mixon is priced as near-waiver wire. If he signs with an RB-needy team and clears medicals, the buy price is negligible — a small-capital speculative flier with meaningful upside if he recaptures even 80% of his 2024 form.

His last active season (2024) produced 1,000+ rushing yards and 11 TDs with C.J. Stroud and the Texans offensive line. That baseline confirms his tools are intact if the foot is genuinely resolved — a clean bill of health would trigger immediate re-evaluation.

Seattle's backfield has significant instability (Charbonnet ACL, Walker III departed), and the Seahawks have been floated as a legitimate suitor. A Seahawks landing would offer a path to meaningful early-down snaps in a run-friendly system — the clearest upside scenario available.

Mixon's 2024 game logs (his last active season) show genuine pass-catching utility — 11% target share and 53% snaps in Week 20, 16.9 points in Week 19. A PPR or half-PPR landing spot with a pass-first offense could produce flex-relevant weeks even in a committee.